Utility of Respiratory Biomarker Guidance in Exacerbations
brief summary
People with asthma or chronic obstructive pulmonary disease (COPD) often come to the emergency department because their breathing suddenly gets worse. These flare-ups are called exacerbations. Many of these episodes are caused by viruses or inflammation, not bacteria. However, clinicians still frequently prescribe antibiotics, even when they are unlikely to help. Unnecessary antibiotic use can cause side effects, increase healthcare costs, and contribute to antibiotic resistance, which is a growing public health problem. The URGE study aims to find a better way to decide when antibiotics are truly needed during asthma or COPD attacks in the emergency department. The study will test whether using two rapid bedside tests can safely reduce unnecessary antibiotic prescriptions. The first test is a rapid molecular test that looks for common respiratory viruses and certain bacteria using a nasopharyngeal swab. Results are available within about 15 to 20 minutes. The second test measures C-reactive protein (CRP) from a small blood sample. CRP is an inflammation marker that tends to be higher when a bacterial infection is present. Together, these tests give doctors quick information about whether an infection is likely viral, bacterial, or non-infectious. URGE will recruit 200 adults who come to the emergency department with an asthma or COPD exacerbation to take part in the study. After providing consent, participants will be randomly assigned to one of two groups. In both groups, participants will complete both rapid tests. In one group, the test results will be shared with the treating doctor right away and can be used to help guide treatment decisions. In the other group, the doctor will not see the test results, and care will follow usual practice. Doctors will always be free to make their own clinical decisions, regardless of test results. The main outcome the study will measure is whether or not patients are prescribed antibiotics when they leave the emergency department or are admitted to hospital. The study will also examine how long patients take antibiotics, hospital admissions, return visits to healthcare services, and patient satisfaction. Participants will be followed up by phone and through medical record review at 7 days and 30 days after their emergency visit to ensure they recover safely. The URGE trial will study tests that are already approved and commonly used in healthcare. The goal is not to deny needed treatment, but to better match treatment to the cause of the flare-up. If successful, this approach could reduce unnecessary antibiotic use, improve patient care, and support safer, more sustainable treatment of asthma and COPD exacerbations in emergency departments.
detailed description
Acute exacerbations of asthma and COPD are frequent causes of emergency department (ED) visits worldwide, with a substantial proportion of patients receiving antibiotics - often inappropriately - despite a likely viral or non-infectious etiology \[1,2\]. This practice contributes to antimicrobial resistance, patient harm, and unnecessary healthcare costs \[3-8\]. While guidelines emphasize the judicious use of antibiotics, real-time decision-making in the ED is often constrained by diagnostic uncertainty. Current approaches recommended by guidelines (GINA, GOLD, INESSS) rely heavily on symptom severity and do not systematically integrate host inflammatory or pathogen-specific data \[9-12\].
Leveraging evidence from previous randomized controlled trial post hoc analyses, the URGE trial is a pragmatic, randomized, open-label study designed to evaluate whether dual point-of-care testing (POCT) - combining rapid molecular microbial PCR (Polymerase Chain Reaction) testing and C-reactive protein (CRP) - can reduce antibiotic use in adults presenting to the ED with an asthma or COPD attack. This dual biomarker strategy aims to enhance diagnostic precision by integrating pathogen detection with host inflammatory responses, thereby guiding real-time, targeted decisions.
A total of 200 patients will be targeted, recruiting until at least 124 analysable patients have completed the trial. All participants will undergo microbial PCR and CRP testing after randomisation and will be managed in accordance with current clinical practice guidelines. In the intervention group, PCR and CRP results will be available to treating clinicians at the time of evaluation and used to inform management decisions. In the control group, test results will not be available to clinicians. The primary outcome is the proportion of patients prescribed antibiotics at ED discharge. Secondary outcomes include antibiotic duration, hospital admissions, revisit rates, and patient acceptability.
URGE is grounded in a growing body of evidence suggesting that either molecular microbial PCR alone or CRP can reduce antibiotic prescribing in acute respiratory illness. Molecular microbial POCT enables rapid identification of respiratory pathogens, whereas CRP reflects the host's systemic inflammatory response - particularly in response to bacterial infections- thereby facilitating early exclusion of a bacterial etiology. However, to date, no randomized trials have assessed the combined impact of these two complementary biomarkers in a real-world emergency care setting. URGE is the first study to evaluate whether integrating both markers into a unified triage strategy can synergistically improve antibiotic stewardship in patients with asthma and COPD attacks.
official title
Utility of Respiratory Biomarker Guidance in Exacerbations (URGE): a Pragmatic, Randomized, Open-Label, Single-Center Superiority Trial of Dual Point-of-Care Testing to Reduce Antibiotic Use in Adults Presenting to the Emergency Department With Asthma or COPD Exacerbations